Effect of 0.5% apraclonidine on ptosis in Horner syndrome - PubMed (original) (raw)
Case Reports
Effect of 0.5% apraclonidine on ptosis in Horner syndrome
Daniel C Garibaldi et al. Ophthalmic Plast Reconstr Surg. 2006 Jan-Feb.
Abstract
To demonstrate the effect of apraclonidine on anisocoria and ptosis in Horner syndrome, one drop of 0.5% apraclonidine was instilled in both eyes of 3 patients who presented with acute Horner syndrome, and the effect on ptosis and anisocoria was documented. As reported in the literature, one drop of 0.5% apraclonidine reverses the anisocoria of Horner syndrome. In addition, 0.5% apraclonidine leads to a complete resolution of the ptosis associated with Horner syndrome, a finding reported once in the literature. Apraclonidine is a safe and readily available alternative to cocaine for the diagnosis of Horner syndrome.
Similar articles
- Pharmacologic reversal of Horner's syndrome-related ptosis with apraclonidine.
Chu EA, Byrne PJ. Chu EA, et al. Ear Nose Throat J. 2007 May;86(5):270, 273. Ear Nose Throat J. 2007. PMID: 17580803 No abstract available. - Apraclonidine in the treatment of ptosis.
Wijemanne S, Vijayakumar D, Jankovic J. Wijemanne S, et al. J Neurol Sci. 2017 May 15;376:129-132. doi: 10.1016/j.jns.2017.03.025. Epub 2017 Mar 16. J Neurol Sci. 2017. PMID: 28431598 - False negative apraclonidine test in two patients with Horner syndrome.
Kawasaki A, Borruat FX. Kawasaki A, et al. Klin Monbl Augenheilkd. 2008 May;225(5):520-2. doi: 10.1055/s-2008-1027349. Klin Monbl Augenheilkd. 2008. PMID: 18454417 - The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face.
Scheinfeld N. Scheinfeld N. Dermatol Online J. 2005 Mar 1;11(1):9. Dermatol Online J. 2005. PMID: 15748550 Review. - Positive apraclonidine test 36 hours after acute onset of horner syndrome in dorsolateral pontomedullary stroke.
Lebas M, Seror J, Debroucker T. Lebas M, et al. J Neuroophthalmol. 2010 Mar;30(1):12-7. doi: 10.1097/WNO.0b013e3181b1b41f. J Neuroophthalmol. 2010. PMID: 20182200 Review.
Cited by
- Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials.
Wirta DL, Korenfeld MS, Foster S, Smyth-Medina R, Bacharach J, Kannarr SR, Jaros MJ, Slonim CB. Wirta DL, et al. Clin Ophthalmol. 2021 Oct 8;15:4035-4048. doi: 10.2147/OPTH.S322326. eCollection 2021. Clin Ophthalmol. 2021. PMID: 34675472 Free PMC article. - Horner's syndrome, Pseudo-Horner's syndrome, and simple anisocoria.
Martin TJ. Martin TJ. Curr Neurol Neurosci Rep. 2007 Sep;7(5):397-406. doi: 10.1007/s11910-007-0062-y. Curr Neurol Neurosci Rep. 2007. PMID: 17764630 Review. - Apraclonidine-An eye opener.
Fierz FC, Disse LR, Bockisch CJ, Weber KP. Fierz FC, et al. Front Ophthalmol (Lausanne). 2022 Aug 9;2:902821. doi: 10.3389/fopht.2022.902821. eCollection 2022. Front Ophthalmol (Lausanne). 2022. PMID: 38983513 Free PMC article. - A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options.
Bacharach J, Lee WW, Harrison AR, Freddo TF. Bacharach J, et al. Eye (Lond). 2021 Sep;35(9):2468-2481. doi: 10.1038/s41433-021-01547-5. Epub 2021 Apr 29. Eye (Lond). 2021. PMID: 33927356 Free PMC article. Review. - Persistent Horner Syndrome Following Bilateral Endoscopic Thoracic Sympathotomy: A Case Report.
Lee HJ, Kang JJ, Oh SY. Lee HJ, et al. Neuroophthalmology. 2024 Mar 12;48(5):364-368. doi: 10.1080/01658107.2024.2324397. eCollection 2024. Neuroophthalmology. 2024. PMID: 39145325
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials